Our partner Catalan Institute of Nanoscience and Nanotechnology (ICN2) recently hosted the second consortium meeting of the 2D-BioPAD project on April 17-18, 2024, bringing together key project partners to discuss ongoing progress and future directions of the project.
The first day of the meeting was marked by productive exchanges, where partners presented updates on their work packages, shared milestones, and discussed the latest developments in blood-based biomarkers crucial for early AD detection. A pivotal point of agreement was reached on the targeted biomarkers and essential specifications for developing the 2D-BioPAD Point-of-Care (PoC) In-Vitro Diagnostic (IVD) system.
A special workshop titled “Ethical Consideration Roadmap – Application of Ethics in the 2DBioPAD Project” emphasized the consortium's commitment to ethical standards in technology development. Members from the 2D-BioPAD’s Scientific and Industrial Advisory Board (SIAB) joined the workshop and provided valuable feedback for upcoming activities.
The second day focused on the practical applications of the project, with a tour of ICN2 facilities and detailed discussions on the development of 2D-BioPAD prototypes. The consortium outlined the clinical protocol for upcoming pilot studies aimed at validating the technology in real-world settings.
Further discussions involved collaboration opportunities with the sister project MUNASET, aiming to enhance goals and maximize project impacts through joint efforts.
The consortium plans to continue its rigorous research and development activities, with further meetings scheduled to ensure the project stays on track to meet its objectives.
